The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner

Proceedings of the National Academy of Sciences of the United States of America

Volumn 107, Issue 33, 2010, Pages 14903-14908

  Joseph, Eric W ^a,b   Pratilas, Christine A ^b   Poulikakos, Poulikos I ^b   Tadi, Madhavi ^b   Wang, Weiqing ^b   Taylor, Barry S ^b   Halilovic, Ensar ^a,b   Persaud, Yogindra ^b   Xing, Feng ^b   Viale, Agnes ^b   Tsai, James ^c   Chapman, Paul B ^b   Bollag, Gideon ^c   Solit, David B ^b   Rosen, Neal ^b  

^a Weill Cornell Graduate School of Biomedical Sciences   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c PLEXXIKON INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; PLX 4032; RAF PROTEIN; RAS PROTEIN; BENZAMIDE DERIVATIVE; BRAF PROTEIN, HUMAN; DIPHENYLAMINE; DRUG DERIVATIVE; INDOLE DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; SULFONAMIDE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL MUTANT; CELL PROLIFERATION; CONTROLLED STUDY; DRUG SELECTIVITY; ENZYME ACTIVATION; GENE MUTATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR CELL; TUMOR GENE; TUMOR GROWTH; WILD TYPE; AMINO ACID SUBSTITUTION; APOPTOSIS; CELL CYCLE G1 PHASE; DNA MICROARRAY; DRUG ANTAGONISM; DRUG EFFECT; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MUTATION; PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE; WESTERN BLOTTING;

AMINO ACID SUBSTITUTION; APOPTOSIS; BENZAMIDES; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; DIPHENYLAMINE; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; G1 PHASE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INDOLES; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MUTATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS B-RAF; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SULFONAMIDES;

EID: 77957089182     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1008990107     Document Type: Article

References (38)

1. Robinson MJ, Cobb MH (1997) Mitogen-activated protein kinase pathways. Curr Opin Cell Biol 9:180-186.
2. Davies H, et al. (2002) Mutations of the BRAF gene in human cancer. Nature 417:949-954.
3. Brose MS, et al. (2002) BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res 62:6997-7000.
4. Sebolt-Leopold JS, et al. (1999) Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat Med 5:810-816.
5. Yeh TC, et al. (2007) Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor. Clin Cancer Res 13:1576-1583.
6. Tsai J, et al. (2008) Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci USA 105:3041-3046.
7. Hoeflich KP, et al. (2009) Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression. Cancer Res 69:3042-3051.
8. Solit DB, et al. (2006) BRAF mutation predicts sensitivity to MEK inhibition. Nature 439:358-362.
9. Pratilas CA, et al. (2008) Genetic predictors of MEK dependence in non-small cell lung cancer. Cancer Res 68:9375-9383.
10. Wee S, et al. (2009) PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers. Cancer Res 69:4286-4293.
11. Halilovic E, et al. (2010) PIK3CA mutation uncouples tumor growth and Cyclin D1 regulation from MEK/ERK and mutant KRAS signaling. Cancer Res, in press.
12. Dougherty MK, et al. (2005) Regulation of Raf-1 by direct feedback phosphorylation. Mol Cell 17:215-224.
13. Pratilas CA, et al. (2009) (V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway. Proc Natl Acad Sci USA 106:4519-4524.
14. Friday BB, et al. (2008) BRAF V600E disrupts AZD6244-induced abrogation of negative feedback pathways between extracellular signal-regulated kinase and Raf proteins. Cancer Res 68:6145-6153.
15. Wan PT, et al.; Cancer Genome Project (2004) Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116:855-867.
16. Adjei AA, et al. (2008) Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol 26:2139-2146.
17. LoRusso PM, et al. (2010) Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers. Clin Cancer Res 16:1924-1937.
18. Dummer R, et al. (2008) AZD6244 (ARRY-142886) vs temozolomide (TMZ) in patients (pts) with advanced melanoma: An open-label, randomized, multicenter, phase II study. J Clin Oncol 26: (suppl). Abstract no. 9033.
19. Ichijo H, et al. (1997) Induction of apoptosis by ASK1, a mammalian MAPKKK that activates SAPK/JNK and p38 signaling pathways. Science 275:90-94.
20. Chen J, Fujii K, Zhang L, Roberts T, Fu H (2001) Raf-1 promotes cell survival by antagonizing apoptosis signal-regulating kinase 1 through a MEK-ERK independent mechanism. Proc Natl Acad Sci USA 98:7783-7788.
21. O'Neill E, Rushworth L, Baccarini M, Kolch W (2004) Role of the kinase MST2 in suppression of apoptosis by the proto-oncogene product Raf-1. Science 306:2267-2270.
22. Tsai J, et al. (2006) Development of a novel inhibitor of cogenic b-Raf. AACR Meeting Abstracts 2006 (1):571.
23. Alessi DR, Cuenda A, Cohen P, Dudley DT, Saltiel AR (1995) PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. J Biol Chem 270:27489-27494.
24. Courtois-Cox S, et al. (2006) A negative feedback signaling network underlies oncogene-induced senescence. Cancer Cell 10:459-472.
25. Hall-Jackson CA, et al. (1999) Paradoxical activation of Raf by a novel Raf inhibitor. Chem Biol 6:559-568.
26. Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N (2010) RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 464:427-430.
27. Keyse SM (2008) Dual-specificity MAP kinase phosphatases (MKPs) and cancer. Cancer Metastasis Rev 27:253-261.
28. Kim HJ, Bar-Sagi D (2004) Modulation of signalling by Sprouty: A developing story. Nat Rev Mol Cell Biol 5:441-450.
29. Smalley KS, et al. (2008) Identification of a novel subgroup of melanomas with KIT/cyclin-dependent kinase-4 overexpression. Cancer Res 68:5743-5752.
30. Tsao H, Goel V, Wu H, Yang G, Haluska FG (2004) Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma. J Invest Dermatol 122:337-341.
31. Davies MA, et al. (2009) Integrated molecular and clinical analysis of AKT activation in metastatic melanoma. Clin Cancer Res 15:7538-7546.
32. Heidorn SJ, et al. (2010) Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 140:209-221.
33. Hatzivassiliou G, et al. (2010) RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 464:431-435.
34. Flaherty K, et al. (2009) Phase I study of PLX4032: Proof of concept for V600E BRAF mutation as a therapeutic target in human cancer. J Clin Oncol, 27:(suppl). Abstract no. 9000.
35. Barrett SD, et al. (2008) The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901. Bioorg Med Chem Lett 18:6501-6504.
36. Nüsse M, Beisker W, Hoffmann C, Tarnok A (1990) Flow cytometric analysis of G1- and G2/M-phase subpopulations in mammalian cell nuclei using side scatter and DNA content measurements. Cytometry 11:813-821.
37. Smyth GK (2004) Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 3: Article 3.
38. Eisen MB, Spellman PT, Brown PO, Botstein D (1998) Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 95:14863-14868.